Overview

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Fenretinide
Hormones